We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+15.22%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$148M
(+14%)
Cap. Flow
+$27M
Cap. Flow
% of AUM
2.23%
Top 10 Holdings %
Top 10 Hldgs %
38.39%
Holding
516
New
39
Increased
143
Reduced
266
Closed
39
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$6.89M |
| 2 |
Alibaba
BABA
|
+$4.05M |
| 3 |
iShares Silver Trust
SLV
|
+$4M |
| 4 |
Futu Holdings
FUTU
|
+$3.28M |
| 5 |
Broadcom
AVGO
|
+$3.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAP
SAP
|
+$2.28M |
| 2 |
Tapestry
TPR
|
+$2.13M |
| 3 |
Abbott
ABT
|
+$2.05M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$2.05M |
| 5 |
T-Mobile US
TMUS
|
+$2.03M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 39.61% |
| 2 | Healthcare | 20.82% |
| 3 | Communication Services | 12.95% |
| 4 | Consumer Discretionary | 11.61% |
| 5 | Consumer Staples | 3.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Lyell Immunopharma
LYEL
$347M
| $54.7K | ﹤0.01% |
3,367
+401
| +14% | +$4.58K |
|
|
SCPH
427
DELISTED
scPharmaceuticals
SCPH
| $53K | ﹤0.01% |
9,342
-1,261
| -12% | -$6.46K |
|
428
Alector
ALEC
$240M
| $52.5K | ﹤0.01% |
17,741
-2,342
| -12% | -$5.16K |
|
|
MAZE
429
Maze Therapeutics
MAZE
$1.52B
| $51.9K | ﹤0.01% |
+2,000
| New | +$33.8K |
|
430
Vanda Pharmaceuticals
VNDA
$314M
| $51.7K | ﹤0.01% |
10,357
-1,480
| -13% | -$6.85K |
|
431
Neumora Therapeutics
NMRA
$317M
| $51.7K | ﹤0.01% |
28,387
-4,099
| -13% | -$6.63K |
|
432
AC Immune
ACIU
$267M
| $50.9K | ﹤0.01% |
17,600
-2,567
| -13% | -$5.8K |
|
433
Larimar Therapeutics
LRMR
$454M
| $48.5K | ﹤0.01% |
15,003
+2,143
| +17% | +$8.04K |
|
434
Foghorn Therapeutics
FHTX
$394M
| $48.5K | ﹤0.01% |
9,909
-1,286
| -11% | -$6.82K |
|
435
Humacyte
HUMA
$179M
| $48.3K | ﹤0.01% |
27,760
-3,395
| -11% | -$6.65K |
|
436
Allogene Therapeutics
ALLO
$714M
| $48.2K | ﹤0.01% |
38,892
-5,039
| -11% | -$6.01K |
|
|
KMTS
437
Kestra Medical Technologies
KMTS
$1.64B
| $47.5K | ﹤0.01% |
+2,000
| New | +$35.8K |
|
438
Cartesian Therapeutics
RNAC
$263M
| $46.6K | ﹤0.01% |
4,558
-655
| -13% | -$7.36K |
|
439
Kyverna Therapeutics
KYTX
$489M
| $45.5K | ﹤0.01% |
7,580
-1,100
| -13% | -$4.4K |
|
440
Voyager Therapeutics
VYGR
$197M
| $45.4K | ﹤0.01% |
9,723
-1,391
| -13% | -$5.03K |
|
441
Neurogene
NGNE
$738M
| $43.4K | ﹤0.01% |
2,502
-362
| -13% | -$7.27K |
|
|
SLN
442
Silence Therapeutics
SLN
$641M
| $42.7K | ﹤0.01% |
8,232
-1,214
| -13% | -$6.74K |
|
443
Atea Pharmaceuticals
AVIR
$405M
| $40.3K | ﹤0.01% |
13,910
-3,278
| -19% | -$11.2K |
|
|
TVRD
444
Tvardi Therapeutics
TVRD
$22.1M
| $39K | ﹤0.01% |
+1,000
| New | +$28.5K |
|
445
Entrada Therapeutics
TRDA
$299M
| $38.7K | ﹤0.01% |
6,667
-956
| -13% | -$5.59K |
|
446
Codexis
CDXS
$172M
| $38.6K | ﹤0.01% |
15,823
-816
| -5% | -$2.23K |
|
447
Ironwood Pharmaceuticals
IRWD
$714M
| $37.3K | ﹤0.01% |
28,472
-4,029
| -12% | -$4.17K |
|
448
Immuneering
IMRX
$328M
| $35K | ﹤0.01% |
+5,000
| New | +$25.9K |
|
449
OmniAb
OABI
$497M
| $34.4K | ﹤0.01% |
21,508
-3,063
| -12% | -$5.6K |
|
450
MaxCyte
MXCT
$136M
| $29.5K | ﹤0.01% |
18,687
-2,667
| -12% | -$4.63K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q3 2025 Portfolio in Review
As of Q3 2025, China Universal Asset Management Company held 516 positions worth $1.21B, up 14% from $1.06B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
China Universal Asset Management Company's Q3 2025 filing shows 39 new, 143 increased, 266 reduced and 39 closed positions. Its largest new stake was Alibaba: 30,923 shares worth $5.53M. The largest sale was SAP, an estimated $2.28M.
By sector, the portfolio is most concentrated in Technology at 40% of assets, up from 38% a quarter earlier, followed by Healthcare and Communication Services.
- China Universal Asset Management Company's largest Q3 2025 buy was Alibaba: 30,923 shares worth $5.53M.
- China Universal Asset Management Company added most to NVIDIA in Q3 2025, an estimated $6.89M increase.
- China Universal Asset Management Company's biggest Q3 2025 reduction was SAP, cutting an estimated $2.28M.
- China Universal Asset Management Company fully exited Tapestry in Q3 2025, selling an estimated $2.13M.
- China Universal Asset Management Company's ten largest holdings make up 38% of its $1.21B portfolio in Q3 2025.
- China Universal Asset Management Company opened 39 new positions and closed 39 in Q3 2025.
- China Universal Asset Management Company's portfolio value rose 14% quarter-over-quarter to $1.21B.
Based on China Universal Asset Management Company's 13F filing for Q3 2025, filed 10 Nov 2025.